Study of Steqeyma® biosimilar in Crohn's and psoriasis
Treatments studied
Part of Digestive system clinical trials.
This study follows people with Crohn's disease or plaque psoriasis who are switching from the reference Ustekinumab to a biosimilar (Steqeyma®). It aims to see how well the biosimilar works in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have Crohn's disease or plaque psoriasis.
- You have been taking Ustekinumab (the reference medicine) for at least 6 months.
- Your condition has been stable (no major changes) for at least 3 months.
- Your doctor has decided to switch you to a biosimilar (Steqeyma®) as part of your care.
- You have an email address and a mobile phone, and can fill out surveys in French.
- You are covered by French Social Security and are not pregnant or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
This study tests a new treatment for people with Crohn's disease who have lost response to ustekinumab (Stelara). It aims to see if a different dosing or additional treatment can help regain control of symptoms.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
This study tests an investigational drug called SHR-1139 for people with moderate-to-severe plaque psoriasis who have not responded well to previous biologic treatments. The goal is to see if it can reduce psoriasis symptoms safely.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.